plerixafor (Rx)

  • Print
Brand and Other Names:Mozobil

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

single use injection

  • 20mg/mL (24mg vial)
more...

Stem Cell Transplantation

Mobilization of Hematopoietic Stem Cells to Peripheral Blood for Collection and Subsequent Autoloqous Transplantation in Patients with Non-Hodgkin's Lymphoma (NHL) & Multiple Myeloma

Initiate treatment after patient has received granulocyte-colony stimulating factor (G-CSF) qDay for 4 days

Recommended dose: 0.24 mg/kg SC qDay; repeat up to 4 consecutive days; not to exceed 40 mg/day  

Start treatment approximately 11 hr prior to apheresis initiation

Acute Myeloid Leukemia (Orphan)

Orphan indication sponsor

  • Genzyme Corporation; 500 Kendall Street, Cambridge, MA 02142

Renal Impairment

CrCl >50 mL: Dose adjustment not necessary

CrCl <50 mL/min: Reduce Dose by 1/3 to 0.16 mg/kg; not to exceed 27 mg/day

Safety and efficacy not established

Next:

Adverse Effects

>10%

Diarrhea (37%)

Injection site reaction (34%)

Nausea (34%)

Fatigue (27%)

Headache (22%)

Arthralgia (13%)

Dizziness (11%)

Vomiting (10%)

1-10%

Insomnia (7%)

Flatulence (7%)

Vomiting (10%)

Postmarketing Reports

Immune System Disorders: Anaphylactic reactions, including anaphylactic shock

Abnormal dreams and nightmares

Previous
Next:

Warnings

Contraindications

None listed in the manufacturer's labeling

History of hypersensitivity; anaphylaxis reported

Cautions

Not intended for HSC mobilization and harvest in patients with leukemia

When used in combination with filgrastim tumor cells may be released from the bond marrow and subsequently collected in the leukapheresis product. Effects of potential reinfusion of tumor cells not studied

Dose reduction recommended in patients with moderate-severe renal impairment

Leukocytosis; use in conjunction with G-CSF increases circulating leukocytes as well as HSC populations

Risk of thrombocytopenia; monitor platelet counts in all patients receiving treatment and then undergo apheresis

Risk of splenic enlargement and rupture

Optimal effective dose in patients wighing >175% of ideal body weight not studied

Splenomegaly and splenic rupture reported

Medications that reduce renal function or compete for active tubular secretion may increase serum concentrations of plerixafor

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: D

Lactation: Not known if excreted in breast milk; not recommended

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

A hematopoeitic stem cell mobilizer. Blocks binding of stromal cell-derived factor-1-alpha, found on bond marrow stromal cells, to the CXC chemokine receptor 4 (CXCR4). The inhibition results in the mobilization of progenitor and hematopoietic stem cells from the bone marrow into peripheral blood.

Absorption

Peak Plasma Time: 30-60 min (SC)

Distribution

Protein Bound: 58%

Vd: 0.3 L/kg

Metabolism

None

Elimination

Half-Life: 3-6 hr

Excretion: Urine 70%

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous